FHIR for FAIR - FHIR Implementation Guide, published by Health Level Seven International - SOA Work Group. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/fhir-for-fair/ and changes regularly. See the Directory of published versions
NFDI4Health stands for “National Research Data Infrastructure for Personal Health Data in Germany”. It is part of a network of 30 NFDI consortia covering different scientific disciplines like chemistry or cultural heritage. All NFDIs got a five-year grant (2020-2025) from the German Federal Ministry of Education and Research (BMBF). The main goal is to build a networked infrastructure and connect existing datasets.
NFDI4Health provides a broad coverage of biomedical data-driven projects like:
NFDI4Health is strongly committed to the ideas of FAIR data management. However, as personal and particularly sensitive data, health data are subject to special protection regulations. They may only be made available to third parties with the patient’s consent or after de-identification. Furthermore, accompanying study materials such as protocols, descriptions of data catalogs or data entry forms are in part considered intellectual property and are only published in an incomplete manner.
In the context of the Sars-Cov-2 pandemic, as in many consortia, a special intitiative was created to support research. The NFDI4Health Task Force COVID-19 is developing, among other things, a hub of clinical and epidemiological studies in Germany related to COVID-19: the COVID-19 Study Portal.
The study portal consists of three main parts:
Typical research studies such as SHIP-COVID have a complex structure and can be characterized by a variety of attributes. One problem here is the low consensus on the meaning and value list options of individual attributes. Especially generic attributes such as study type, study focus, primary objective, or target population are understood differently in clinical trials than in epidemiological cohorts. Individual parameters such as phase, arm, or investigational drug are specific to individual research areas.
A custom metadata schema (MDS) with 86 attributes (in version 1.0) was designed for the COVID-19 study portal gathering COVID-19 health research such as studies, questionnaires and documents.
The NFDI4Health Taskforce has been committed to FAIR concepts from the beginning. While discoverability and accessibility were primarily addressed as part of the redevelopment or customization of the web applications described above, interoperability of data was low. Therefore, the possibility of applying the HL7 FHIR standard to improve FAIRness was explored with regards to:
To elevate data FAIRness, we aim to adopt the HL7 FHIR and therefore an initial mapping to HL7 FHIR was performed. The MDS items were each mapped to the FHIR resources
We used HL7 FHIR Version Release 4 (v4.0.1) as mapping target. First results showed that 58% of mapped items were available in FHIR as standard resources. The results are published as a paper on PubMed and archieved on FAIRDOMHub.
A new version of the MDS was released which is currently mapped to FHIR and subsequently FHIR profiles will be built with needed extensions for this use case.
Unfortunately, the adoption of FHIR in clinical research is still low. Most of the problems encountered in mapping the MDS are not due to HL7 FHIR. They are due to unclear meaning or highly divergent usage of many of the characteristics of medical research projects in the community itself. That makes a mapping to community-consented and thus accepted and widely used definitions and value sets difficult. The current status of the FHIR specification with regards to clinical research is largely influenced by clinical trials and not by cohorts, registers, public health surveys and administrative databases.